Trial reportContraception2014
Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial.
Trial report in Contraception, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 67 citations in OpenAlex.
- Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial.Contraception · 2021Trial
- Acceptability of oral dimethandrolone undecanoate in a 28-day placebo-controlled trial of a hormonal male contraceptive prototype.Contraception · 2020Trial
- Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men.Andrology · 2019Trial
- Socio-behavioral factors linked to willingness to use new male contraceptives: A cross-sectional survey of men and female partners across four low- and middle-income countries.Contraception · 2026Article
- Transdermal Drug Delivery Systems: Methods for Enhancing Skin Permeability and Their Evaluation.Pharmaceutics · 2025Review
- The uniqueness of on-demand male contraception.Molecular aspects of medicine · 2024Review
- Reversible male contraception by targeted inhibition of serine/threonine kinase 33.Science (New York, N.Y.) · 2024Article
- Male contraception: narrative review of ongoing research.Basic and clinical andrology · 2023Review
- Post-abortion contraception, an opportunity for male partners and male contraception.Contraception · 2022Article
- Hormonal Male Contraception: Getting to Market.Frontiers in endocrinology · 2022Article
- Update on Novel Hormonal and Nonhormonal Male Contraceptive Development.The Journal of clinical endocrinology and metabolism · 2021Review
- What About Methods for Men? A Qualitative Analysis of Attitudes Toward Male Contraception in Burkina Faso and Uganda.International perspectives on sexual and reproductive health · 2020Article
- Male Contraception.The Yale journal of biology and medicine · 2020Review
- Development of Novel Male Contraceptives.Clinical and translational science · 2020Review
- F5-peptide enhances the efficacy of the non-hormonal male contraceptive adjudin.Contraception · 2019Article
- Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel.Andrology · 2019Article
- Are men ready to use thermal male contraception? Acceptability in two French populations: New fathers and new providers.PloS one · 2018Article
- Male Contraception: Research, New Methods, and Implications for Marginalized Populations.American journal of men's health · 2017Review
- Male hormonal contraception: hope and promise.The lancet. Diabetes & endocrinology · 2017Review
- Hormonal, chemical and thermal inhibition of spermatogenesis: contribution of French teams to international data with the aim of developing male contraception in France.Basic and clinical andrology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveFifty percent of pregnancies in the United States are unintended despite numerous contraceptive methods available to women. The only male contraceptive methods, vasectomy and condoms, are used by 10% and 16% of couples, respectively. Prior studies have shown efficacy of male hormonal contraceptives in development, but few have evaluated patient acceptability and potential use if commercially available. The objective of this study is to determine if a transdermal gel-based male hormonal contraceptive regimen, containing testosterone and Nestorone® gels, would be acceptable to study participants as a primary contraceptive method. STUDY
designAs part of a three-arm, 6-month, double-blind, randomized controlled trial of testosterone and nestorone gels at two academic medical centers, subjects completed a questionnaire to assess the acceptability of the regimen. Of the 99 men randomized, 79 provided data for analysis.
resultsOverall, 56% (44/79) of men were satisfied or extremely satisfied with this gel-based method of contraception, and 51% (40/79) reported that they would recommend this method to others. One third of subjects (26/79) reported that they would use this as their primary method of contraception if it were commercially available today. However, men with concerns about sexually transmitted disease were significantly less satisfied than men without such concerns (p=0.03).
conclusionsA majority of the men who volunteered to participate in this trial of an experimental male hormonal contraceptive were satisfied with this transdermal male hormonal contraceptive. If commercially available, a combination of topical nesterone and testosterone gels could provide a reversible, effective method of contraception that is appealing to men. IMPLICATIONS: A substantial portion of men report they would use this transdermal male contraceptive regimen if commercially available. This method would provide a novel, reversible method of contraception for men, whose current choices are limited to condoms and vasectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.